703 related articles for article (PubMed ID: 26099511)
1. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
Zhang XL; Zhu QQ; Zhu L; Chen JZ; Chen QH; Li GN; Xie J; Kang LN; Xu B
BMC Med; 2015 Jun; 13():123. PubMed ID: 26099511
[TBL] [Abstract][Full Text] [Related]
2. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of alirocumab for the treatment of hypercholesterolemia.
Farnier M
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1307-23. PubMed ID: 26563849
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
Stein EA; Giugliano RP; Koren MJ; Raal FJ; Roth EM; Weiss R; Sullivan D; Wasserman SM; Somaratne R; Kim JB; Yang J; Liu T; Albizem M; Scott R; Sabatine MS;
Eur Heart J; 2014 Sep; 35(33):2249-59. PubMed ID: 24598985
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.
Sattar N; Preiss D; Robinson JG; Djedjos CS; Elliott M; Somaratne R; Wasserman SM; Raal FJ
Lancet Diabetes Endocrinol; 2016 May; 4(5):403-10. PubMed ID: 26868195
[TBL] [Abstract][Full Text] [Related]
9. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
[TBL] [Abstract][Full Text] [Related]
10. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
[TBL] [Abstract][Full Text] [Related]
11. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
12. Evolocumab (AMG 145) for primary hypercholesterolemia.
Langslet G; Emery M; Wasserman SM
Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
[TBL] [Abstract][Full Text] [Related]
13. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
14. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
[TBL] [Abstract][Full Text] [Related]
19. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
Roth EM; Taskinen MR; Ginsberg HN; Kastelein JJ; Colhoun HM; Robinson JG; Merlet L; Pordy R; Baccara-Dinet MT
Int J Cardiol; 2014 Sep; 176(1):55-61. PubMed ID: 25037695
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
